PRODUCT

고객만족을 위해 지속적으로 고민하고 혁신하여 최고의 품질을 제공합니다.

search

R&D reagents

Product > R&D reagents
Galantamine hydrobromide, 98% (HPLC)
CAS No 69327-100mg
제품번호 AK Sci.(USA)
제조사 수입산
재고 1 EA
금액 146,000원
포장단위
포장단위



Nivalin
Razadyne




※ 화학명 : Galantamine hydrobromide, 98% (HPLC)

 

※ 등급 : APIs and Bioactives > AChR Agonists, Alzheimers

 

※ 판매 포장단위 : 100mg , 500g , 1g

 

※ 화학식 : C17H22BrNO3

 

※ CAS # : [1953-04-4]


 

IDENTITY
CAS Registry #:

 

[1953-04-4]

MDL Number: MFCD00067672
MF: C17H22BrNO3
MW: 368.2655
EINECS: 217-780-5
BRN: 3787265
SPECIFICATIONS & PROPERTIES
Purity: 98% (HPLC)
Available Spectra: LCMS, HPLC, Polarimetry
Physical Form: White to off-white to light yellow powder or crystals
Melting Point: 256°C
Optical Rotation: -92.0 to -98.0° (c=1.4, H2O)

Long-Term Storage:

 

Store long-term at -20°C

Shipping: Regulated for Shipping
UN #: 2811
Hazard Class: 6.1
Packing Group: III

BIOLOGICAL INFO
Solubility: Water: 20mg/mL; Soluble in ethanol
Application(s): Reversible acetylcholinesterase inhibitor

REVIEW
Galantamine is a phenanthrene alkaloid and a reversible, competitive acetylcholinesterase inhibitor. It is not structurally related to other acetylcholinesterase inhibitors. Galantamines proposed mechanism of action involves the reversible inhibition of acetylcholinesterase, which prevents the hydrolysis of acetycholine, leading to an increased concentration of acetylcholine at cholinergic synapses. Galantamine also binds allosterically with nicotinic acetylcholine receptors and may possibly potentiate the action of agonists (such as acetylcholine) at these receptors.
REFERENCES
[1] Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimers disease. Drugs. 2000 Nov;60(5):1095-122.
[2] Greenblatt HM, Kryger G, Lewis T, Silman I, Sussman JL: Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 A resolution. FEBS Lett. 1999 Dec 17;463(3):321-6.
[3] Woodruff-Pak DS, Vogel RW 3rd, Wenk GL: Galantamine: effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning. Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):2089-94. Epub 2001 Feb 6.
[4] Birks J: Cholinesterase inhibitors for Alzheimers disease. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005593. Pubmed# Lilienfeld S: Galantamine-a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimers disease. CNS Drug Rev. 2002 Summer;8(2):159-76.

Risk Description(s)
R25: Toxic if swallowed.

Safety Description(s)
S45: In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible).